Advancing cancer immunotherapy: Unveiling the potential of PD-L1-targeted IFN-α2a DutaFlip molecule through patient-derived tumor explants
Key challenges in Oncology
Development of preclinical models that fully represent the human immunity and the complexity of human tumors including all hallmarks of cancer.
Choosing the most translationally-relevant model to study the mode of action (MoA) of a new drug is one of the real difficulties for cancer research.
Patient derived tumor explants (PTEs)
- Obtained from patients during surgery or biopsy
- Include primary tumors, metastases, or recurrent tumors, providing a diverse representation of disease stages
- Recapitulate the features of a patient tumor and its tumor microenvironment (TME)
- Cell-cell interactions and tumor microenvironment architecture
- Metabolic features
-
-
- Conference: AACR 2025, Chicago
- Authors: Steffen Dettling1, Martina Antoniolli2, Kerstin Paetzold2, Manuela Gies2, Jakob Rosenhauer2, Jens Liedke2, David Lamparter1, Tai-Hsien Ou Yang1, Petra Schwalie1, Sina Nassiri1, Emre Koese1, Hans J. Grote2, Natascha Rieder2, Gabriel Schnetzler1, Rober Mader1, Andreas Roller1, Moritz Rapp2, Meher Majety1, Marina Bacac3, Pablo Umana3
-
1 Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel – Switzerland
2 pRED, Roche Innovation Center Munich, Penzberg – Germany
3 pRED, Roche Innovation Center Zürich, Zürich – Switzerland
Fill the form below to get your copy
Check your email! You will receive soon a message from us with the copy requested.
Other Posters
All Resources
Never stop learning!
Check publications from the team, protocols, and useful information to boost your research and get into organ on chip technology!